ArticleTherapeutic advances in respiratory disease
Neutrophil elastase activity in bronchial lavage fluid and the one-year follow-up outcomes in bronchiectasis patients: A multicenter prospective cohort study.
Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bronchoscopy in bronchiectasis: value of lavage beyond microbiology.ERJ open research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundBronchiectasis is increasingly recognized as an inflammatory disease in which "disease activity" is not fully captured by radiology or composite severity scores. Although sputum neutrophil elastase (NE) activity is a validated biomarker, the prognostic value of segment-specific NE activity in bronchial lavage fluid (BLF) remains limited.ObjectivesTo evaluate NE activity in BLF collected from affected bronchi and determine its association with one-year bronchiectasis outcomes.DesignMulticenter prospective cohort study.MethodsAdults with stable bronchiectasis undergoing bronchoscopy at two hospitals in Ho Chi Minh City were enrolled between April 2022 and January 2024. BLF was collected from the most affected bronchus (ABLF) and a reference bronchus (NBLF). NE activity was quantified using a fluorogenic assay. Participants were followed for 12 months to assess exacerbations and time to first exacerbation.ResultsOf 168 screened patients, 139 were enrolled and 121 completed follow-up. Post-tuberculosis bronchiectasis was the most common etiology. NE activity was detectable in all BLF samples and was higher in ABLF than NBLF (median 2.0 vs. 0.4 μg/mL). Exacerbations occurred in 42.1% of patients. ABLF NE activity was higher in patients with chronic bacterial infection than in those without (median 3.6 vs. 1.8 μg/mL; p=0.001), and in patients who developed exacerbations compared with those who did not (median 3.0 vs. 1.2 μg/mL; p<0.001). After adjustment for baseline severity indices, higher ABLF NE activity remained associated with increased exacerbation risk. Kaplan-Meier analysis showed shorter exacerbation-free survival with increasing ABLF NE activity, with estimated mean exacerbation-free survival times of 10.5, 8.5, and 6.9 months in the mild, moderate, and high NE groups, respectively (log-rank p=0.001).ConclusionSegment-specific NE activity in BLF is elevated in affected bronchi and is an independent predictor of exacerbations in this TB-endemic Asian bronchiectasis cohort, supporting BLF NE as a clinically meaningful biomarker of disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.